TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Rapid Assessment of Esophageal Adenocarcinoma Risk Test

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Males:~Ages 50-75 and at least one of the following:~* Gastro-esophageal reflux disease (GERD)\* or~* Family history (first degree relative) with Barrett's esophagus or esophageal adenocarcinoma or~* Both body mass index (BMI) ≥30 or~* A history of cigarette smoking (at least 10 pack years)~Females:~Ages 50-75 and GERD\* and at least one of the following:~* Family history (first degree relative) with Barrett's esophagus or esophageal adenocarcinoma or~* BMI ≥30 or~* A history of cigarette smoking (at least 10 pack years)~Exclusion Criteria:~* History of gastric or esophageal cancer~* History of esophageal surgery~* Known untreated esophageal stricture or uninvestigated dysphagia~* Previous upper endoscopy within 10 years~* Cancer within 3 years except for non-melanoma skin cancer~* Portal hypertension, with or without known varices~* Uncontrolled coagulopathy~* Uncontrolled major comorbid illness~* Inability to tolerate or contraindication to upper endoscopy~* Inability to give informed consent~GERD defined as either a history of frequent heartburn or fluid regurgitation symptoms (at least weekly for 6 months) or regular use of proton pump inhibitors or histamine-2 receptor antagonists.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cytosponge Test (Type: OTHER): This arm will include individuals without formal diagnosis of Barrett's esophagus.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Effect of Perioperative Caloric Restriction Program on Perioperative Outcomes in Patients With Obesity and Endometrial Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed with Endometrial Cancer~* BMI30 kg/m2~* 18 year of age or older~* Scheduled for definitive surgical intervention (hysterectomy, bilateral salpingoopherectomy with or without lymphadenectomy) in the following 2-3 weeks as part of the standard of care~* Have ECOG performance status of 0-1~* Have a life expectancy of at least 1 year~Exclusion Criteria:~* Inability to communicate in English~* BMI30 kg/m2~* Age18~* Have any uncontrolled serious medical or psychiatric conditions that would affect their ability to participate in an intervention study, (e.g., severe/uncontrolled diabetes mellitus, severe cardiac and/or pulmonary disease and/or depression)~* Diagnosed with any other invasive malignancy currently, in the last five years or expected to undergo active treatment with either cytotoxic chemotherapy or radiation during the 6 week caloric restriction period

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Calorie Restricted (CR) program (Type: OTHER): The intervention will provide individualized CR program, meal replacement products and nutritional counseling sessions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Concentrated Citrate Locking to Reduce the Incidence of CVC-related Complications in Hematological Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with hematological malignancies who were going to receive a CVC for intensive chemotherapy including patients for stem cell transplantation~* written informed consent~* 18 years or older~Exclusion Criteria:~* the presence of a central venous catheter at admission~* history of central venous catheter related thrombosis or infection~* indication for anticoagulant treatment or prophylaxis~* patients with totally implanted catheters~* catheters impregnated with antimicrobial agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A: heparin (Heparin LEO) (Type: ACTIVE_COMPARATOR): After each use, the central venous catheter lumen will be flushed with 10 ml 0.9% NaCl and then locked with heparin 5000 IU/ml(standard treatment)using a volume exactly equivalent to the internal volume noted on each catheter.
- B: concentrated citrate (Citralock) (Type: EXPERIMENTAL): locking the central venous catheter with concentrated citrate after each use

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Photon/Proton Radiation Therapy for Carcinoma of the Nasopharynx

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~\* Nasopharynx cancer.~Exclusion Criteria:~* Evidence of distant metastasis.~* Previous radiation for head and neck cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Photon/Proton Radiation Therapy (Type: None): Photon/Proton Radiation Therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Studying Fentanyl in Patients With Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of cancer~* Inpatient at the Johns Hopkins Hospital Cancer Center undergoing pain treatment with continuous infusion fentanyl citrate for ≥ 5 days~PATIENT CHARACTERISTICS:~* Willing to change to an alternative opioid~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* At least 72 hours since transdermal fentanyl citrate administration~* At least 12 hours since transmucosal fentanyl citrate administration~* No known requirement for continued opioid therapy with any fentanyl citrate products after discontinuation of fentanyl citrate therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: None): receiving fentaly citrate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Interest of the TcPO2 Technique

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* referred for an oximetry exercise test~* Patient able to walk on a treadmill~* Patient covered by the French health insurance~* Patient able to understand the protocol~* Patient agrees to be involve in the protocol and sign the consent form~Exclusion Criteria:~* any heart issues during the last 3 months~* pregnancy

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: NuvaRing Versus Marvelon in the Coordination of In Vitro Fertilization Cycles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed consent form~* Age 18 or above at the time of selection~* In Vitro Fertilization referral~* Complete and normal pre-In Vitro Fertilization check-up~* Long protocol prescription~* No previous participation in the project during a previous cycle~Exclusion Criteria:~* Simultaneous participation in another interventional research project~* Contraindications of being pregnant or carrying a pregnancy to full term~* Contraindications of taking standard medication for long protocol~* Contraindications of taking Marvelon or using NuvaRing (Uncontrolled high blood pressure, uncontrolled diabetes, active hepatic infection, benign or malignant hepatic tumors, diagnosed breast cancer, diagnosed or suspected estrogen-dependant neoplasia, ocular or suspected lesion, history of thrombophlebitis, cardiac arrest, coronary heart disease.)~* Patient presenting vaginal abnormalities could be unable to insert the NuvaRing~* Cervicitis, vaginitis, erosio portionis bleeding, cervical prolapse, cystocele, rectocele, severe or chronic constipation, dyspareunia or other problems with sexual intercourse~* Patient having received research medication 30 days before visit 1~* Patient is unable to communicate adequately with researchers~* Patient is incapable of giving informed consent~* Any ovarian or abdominal abnormalities could interfere with an adequate sonographic evaluation~* Use of the following medication:~* Clonidine~* Anticoagulants (before the anovulant pre-treatment)~* Anticonvulsants~* Oral or insulin hypoglycemia drugs~* Hypertension drugs (beta blockers)~* Aminocaproic acid~* Beta mimetics (isoproterenol)~* Prednisone~* Ciclosporin~* Meperidine~* Phenothiazine and reserpine~* Chlordiazepoxide, Lorazepam, Oxazepam, Diazepam (during the anovulant pre-treatment)~* Theophylline~* Clomipramine~* Vitamin B12~* Hypericum perforatum-based products

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 43 Years
- Healthy Volunteers: f

Study Arms:
- NuvaRing (Type: EXPERIMENTAL): Patients in the NuvaRing group will be inserting the vaginal ring for a period specified by the administrative nurse, ranging from 14 to 35 days.
- Marvelon (Type: ACTIVE_COMPARATOR): Patients on Marvelon will be taking the medication for a period ranging from 14 to 21 days. This period will be determined by the administrative nurse.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ribavirin for Severe Acute and Chronic Hepatitis E Virus Infection.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age equal or greater than 18 years.~* To comply with any of the following diagnoses:~* chronic Hepatitis E: HEV RNA detectable in patients with elevated transaminase levels for at least 6 months and / or HEV RNA detectable in two separated determinations by an interval of six months .~* severe acute Hepatitis E: alanine aminotransferase (ALT) levels greater than 10 times the normal limit, with HEV RNA positive, and signs of acute liver injury (International normalized ratio(INR\> 1.5)); or with extrahepatic manifestations or liver failure in patients with previous liver disease.~* Signed informed consent~Exclusion Criteria:~* Terminal illness with a expected life expectancy of less than 6 months~* Patients with contraindications for treatment with Ribavirin:~* pregnancy or lactation.~* Severe hepatic impairment or decompensated cirrhosis.~* hemoglobinopathies (thalassemia, sickle cell anemia).~* history of severe pre-existing cardiac disease, including unstable heart disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: OTHER): Patients will receive ribavirin during 12 weeks
- Group B (Type: OTHER): Patients will receive:~* ribavirin during 12 weeks if RNA (Ribonucleic acid) Hepatitis E virus (HEV) is undetectable at week 4 after treatment start (adjust to renal function)~* - ribavirin during 24 weeks if RNA (Ribonucleic acid) Hepatitis E virus (HEV) is detectable at week 4 after treatment start (adjust to renal function)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sodium Supplementation and Growth in Very Low Birth Weight Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* infants born at less than 32 weeks postmenstrual age~Exclusion Criteria:~* infants with major malformations deemed incompatible with life disease states characterized by edema renal failure, defined as an increase in serum creatinine by 0.5 mg/dl/day or urine output less than 0.5 ml/kg/hour

- Gender: ALL
- Minimum Age: 7 Days
- Maximum Age: 8 Days
- Healthy Volunteers: f

Study Arms:
- Sodium chloride (Type: ACTIVE_COMPARATOR): Sodium chloride 1 meq/kg (0.4 ml/kg of 2.5meq/ml formulation for injection)q6hrs on days of life 7-35. Intervention was given enterally if feedings were at least 100 ml/kg/day; otherwise medication was diluted in equal amounts of dextrose 5% water and administered intravenously.
- sterile water (Type: PLACEBO_COMPARATOR): Sterile water, 0.4 ml/kg q6hrs on days of life 7-35. Placebo is given enterally when infant is tolerating at least 100 ml/kg/day; otherwise the product is diluted in equal amounts of dextrose 5% water and administered intravenously.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: NewBreez for Airway Protection in Head and Neck Cancer Patients With Chronic Aspiration

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* History of head and neck cancer~* Chronic aspiration~* Currently has a tracheostomy~* Patient is able to independently maintain their tracheostomy and cannula apparatus~* Patient meets the CE Mark indications and are not contraindicated for a NewBreez procedure.~* Anatomically compatible with the available sizes of NewBreez®~* 18 years of age or older~* Sufficient cognitive function to comply with the study and follow-up requirements~* Patient gives voluntary signed informed consent~Exclusion Criteria:~* Recurrent or present cancer in the previous 12 months~* Absent cough reflex~* Severely disrupted swallowing function e.g. severe neurological deficit, absent swallowing reflex, severe fixation of the larynx due to scarring with absent elevation of the larynx~* Upper esophageal sphincter not functional e.g. remains closed~* Cor Pulmonale / Pulmonary Heart Disease, or current lung infection~* Mouth opening less than 3.5cm~* Neck extension severely restricted hindering implantation of the device~* Contraindication to general anesthesia~* Severe hyperostosis (spondylophytes) of the cervical vertebrae causing dysphagia~* Severe (radiogenic) edema or damage of the mucosa of the upper aerodigestive tract

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NewBreez (Type: None): The study group is composed only of patients who have already opted to receive the NewBreez device as part of their routine care from their physician.~Patients who have the device implanted, and consent to be part of the 12 week observational study, will be enrolled and have standard clinical parameters measured over the 12 week period as well as complete quality of life assessments in the form of patient questionnaires.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Phenylephrine for Oral Mucositis Prevention

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* cancer patients scheduled to receive at least 5 weeks of radiation therapy to the sub-mandibular lymph nodes~* normal ECG~* normal blood pressure~Exclusion Criteria:~* untreated cardiac disease~* connective tissue disorders~* open sores, wound, ulcerations to oral cavity~* allergy to phenylephrine~* know untreated hypertensin~* abnormal ECG in past 6 months~* taking prescription monoamine oxidase inhibitor (MAOI)~* are pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1.25 mg phenylephrine (Type: EXPERIMENTAL): None
- 2.5 mg phenylephrine (Type: EXPERIMENTAL): None
- 5.0 mg phenylephrine (Type: EXPERIMENTAL): None
- 10.0 mg phenylephrine (Type: EXPERIMENTAL): None
- 20.0 mg phenylephrine (Type: EXPERIMENTAL): None
- 40.0 mg phenylephrine (Type: EXPERIMENTAL): None
- 60.0 mg phenylephrine (Type: EXPERIMENTAL): None
- 80.0 mg phenylephrine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Non-invasive Brain Stimulation for the Treatment of Depression Symptoms in ALS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of familial or sporadic ALS as well as other Neurodegenerative disorders. Verification of the diagnosis will be performed by the Principal Investigator. This diagnosis can include neuro-degenerative disorders of uncertain cause, including ALS, MND, Peripheral neuropathies, Parkinson's and other progressive motor system diseases.~2. If subjects has ALS diagnosis, the date of dx should be ≤ 2 years~3. Age 18 or older.~4. Capable of providing informed consent.~5. Minimal speech impairment.~6. Ability to comply with study procedures.~7. Ability to communicate clearly if the subject wants to withdraw from the procedure at any stage.~8. MMSE ≥20~9. Female subjects of child bearing potential must engage in abstinence for the duration of the study. If a participant becomes sexually active, she must agree to using the following birth control methods:~   1. Hormonal (oral, implanted, injected, etc)~  2. Intrauterine device in place for ≥ 3 months~  3. Adequate barrier method in conjunction with spermicide~  4. Other~10. Absence of exclusion criteria.~EExclusion Criteria~1. Unable to provide informed consent~2. Significant speech impairment~3. Inability to comply with the procedures~4. Subjects with ALS diagnosis ≥ 2 years~5. Inability to communicate clearly if the subject wants to withdraw from the procedure at any stage~6. Seizures or history of seizures~7. Patients who have underwent brain surgery for any indication~8. Patients with pacemakers, cochlear implants, brain stimulators, infusion pumps, intracardiac lines, metallic clips, other implanted electronic or ferroelectric metallic devices. Dental implants are permitted~9. Inability to perform either TMS or NCS studies due to insufficient MEP or CMAP amplitude.~10. Patients with uncontrolled hypertension~11. Patients with neuro endocrine disorders~12. Patients who are withdrawn from the following drugs within 6 months:~    * Barbiturates~   * Benzodiazepines~   * Meprobamate~   * Chloral hydrate~Patients who have a recent history (within 24h) or chronic history of intake of:~* Cocaine.~* Phencyclidine Phosphate.~* Gamma-Hydroxy Butyrate.~* Amphetamines including N-methylamphetamine, 3,4-Methylenedioxymethamphetamine, 2,5-dimethoxy-4-methylamphetamine, Ephedrine, Cathinone.~  12. Substance abuse+ 13. Excessive use of alcohol # 14. MMSE ≤19 15. Female patients of child bearing potential not practicing contraception 16. Female patients who are pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- intervention (Type: EXPERIMENTAL): rTMS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Development of Imaging Biomarkers for Voice After Pediatric Airway Reconstruction

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Study Patients~Inclusion Criteria:~1. Ages of 3-30 years,~2. No prior airway surgery~3. Able to undergo the evaluation protocol~Exclusion Criteria:~1.) Patients who have undergone any prior airway reconstruction and/or have a disability that precludes them from completing the evaluation~Control Patients~Inclusion Criteria:~1. Age of 3-30 years~2. No prior history of intubation injury or airway/laryngeal surgery~3. Normal hearing~4. Normal voice assessment performed by a certified speech-language pathologist 5.) Undergoing a non-airway surgical procedure such as adenoidectomy, tonsillectomy, ear tubes, and neck mass removal.~Exclusion Criteria:~1. Has had airway or laryngeal surgery~2. History of a voice or hearing disorder~3. History of neonatal intubation over 14 days~4. Have a disability that precludes them from completing the evaluation

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Study: Airway Reconstruction Patients (Type: EXPERIMENTAL): These participants have significant airway abnormalities that require invasive surgery, such as Laryngotracheoplasty, to rectify, and whose voice quality may suffer as a result of the surgery. The goal of this study is to improve voice outcomes of these patients, and their clinical data will be collected.
- Control: Normal Airway Patients (Type: EXPERIMENTAL): These participants have normal airways and voice who will undergo a microlaryngoscopy and voice evaluation, the data from which will be compared to study patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues